Information Provided By:
Fly News Breaks for September 9, 2015
GSK
Sep 9, 2015 | 06:13 EDT
JPMorgan analyst James Gordon believes shares of GlaxoSmithKline have 3% downside after the Breo SUMMIT trial failed to meet its endpoint. The analyst has an Underweight rating on the stock.
News For GSK From the Last 2 Days
There are no results for your query GSK